MX341946B - Composicion y formulacion que comprende iduronato - 2 - sulfatasa humana recombinante y metodo de preparacion de la misma. - Google Patents

Composicion y formulacion que comprende iduronato - 2 - sulfatasa humana recombinante y metodo de preparacion de la misma.

Info

Publication number
MX341946B
MX341946B MX2013015127A MX2013015127A MX341946B MX 341946 B MX341946 B MX 341946B MX 2013015127 A MX2013015127 A MX 2013015127A MX 2013015127 A MX2013015127 A MX 2013015127A MX 341946 B MX341946 B MX 341946B
Authority
MX
Mexico
Prior art keywords
composition
sulfatase
formulation
preparation
recombinant human
Prior art date
Application number
MX2013015127A
Other languages
English (en)
Other versions
MX2013015127A (es
Inventor
Jin Thong-Gyu
Kyung Chung Yo
Hoon Paik Sang
Chang Park Yoo
Seo Jinwook
Woon Choi Yong
Mun Son Jong
Kim Yong-Chul
Original Assignee
Green Cross Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46716009&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX341946(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Green Cross Corp filed Critical Green Cross Corp
Publication of MX2013015127A publication Critical patent/MX2013015127A/es
Publication of MX341946B publication Critical patent/MX341946B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Abstract

La presente invención se refiere a una composición que comprende iduronato-2-sulfatasa (IDS) recombinante. El patrón de glicosilación y contenido de formilglicina de la composición de IDS son diferentes de aquel de Elaprase y tienen eficacia farmacéutica superior y son más seguras que el agente convencional y por lo tanto, puede utilizarse efectivamente para la terapia del síndrome de Hunter.
MX2013015127A 2011-06-24 2012-06-15 Composicion y formulacion que comprende iduronato - 2 - sulfatasa humana recombinante y metodo de preparacion de la misma. MX341946B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161500994P 2011-06-24 2011-06-24
KR1020120012718A KR101158673B1 (ko) 2011-06-24 2012-02-08 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
PCT/KR2012/004734 WO2012177020A2 (en) 2011-06-24 2012-06-15 Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof

Publications (2)

Publication Number Publication Date
MX2013015127A MX2013015127A (es) 2014-06-11
MX341946B true MX341946B (es) 2016-09-08

Family

ID=46716009

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015127A MX341946B (es) 2011-06-24 2012-06-15 Composicion y formulacion que comprende iduronato - 2 - sulfatasa humana recombinante y metodo de preparacion de la misma.

Country Status (28)

Country Link
US (2) US9206402B2 (es)
EP (1) EP2723369B2 (es)
JP (2) JP5844459B2 (es)
KR (2) KR101158673B1 (es)
CN (1) CN103635203B (es)
AU (2) AU2012274215B2 (es)
BR (1) BR112013032193A2 (es)
CA (1) CA2839674C (es)
CO (1) CO6862105A2 (es)
CY (1) CY1117861T1 (es)
DK (1) DK2723369T4 (es)
EA (1) EA026499B1 (es)
ES (1) ES2575377T5 (es)
FI (1) FI2723369T4 (es)
HK (1) HK1195731A1 (es)
HR (1) HRP20160490T4 (es)
HU (1) HUE027431T2 (es)
IL (1) IL230120B (es)
MX (1) MX341946B (es)
MY (1) MY166647A (es)
PE (1) PE20140734A1 (es)
PL (1) PL2723369T5 (es)
PT (1) PT2723369E (es)
RS (1) RS54822B2 (es)
SI (1) SI2723369T2 (es)
SM (1) SMT201600194B (es)
UA (1) UA109949C2 (es)
WO (1) WO2012177020A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012101671A1 (en) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US20140004097A1 (en) * 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
CN106153745B (zh) * 2015-03-31 2020-11-10 三生国健药业（上海）股份有限公司 抗体蛋白二硫键配对分析方法
CN106153746B (zh) * 2015-03-31 2020-11-06 三生国健药业（上海）股份有限公司 IgG2型单抗二硫键配对分析方法
CN106153744B (zh) * 2015-03-31 2020-11-10 三生国健药业（上海）股份有限公司 融合蛋白二硫键配对分析方法
KR20170004814A (ko) * 2015-07-02 2017-01-11 주식회사 녹십자 헌터증후군 치료제
WO2017003270A1 (ko) * 2015-07-02 2017-01-05 주식회사 녹십자 헌터증후군 치료제 및 치료방법
SG11201805598WA (en) * 2015-12-30 2018-07-30 Green Cross Corp Methods and compositions for treating hunter syndrome
US20190055513A1 (en) * 2016-02-22 2019-02-21 Agency For Science, Technology And Research Cell culture medium
KR20190139951A (ko) 2017-04-14 2019-12-18 리젠엑스바이오 인크. 인간 뉴런 또는 신경교 세포에 의해 생성된 재조합 인간 이두로네이트-2 설파타제(ids)를 이용한 뮤코다당증 ii형의 치료
WO2019022563A2 (ko) * 2017-07-28 2019-01-31 한미약품 주식회사 이두로네이트 2-설파타제 결합체
MA50746A (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
KR20190136271A (ko) 2018-05-30 2019-12-10 주식회사 녹십자 대뇌 측뇌실 투여에 의해 헌터증후군을 치료하기 위한 방법 및 조성물
EP3846780A4 (en) * 2018-09-05 2022-11-30 Sangamo Therapeutics, Inc. ENZYMATIC TESTS FOR QUANTIFICATION OF THERAPY IN PATIENTS WITH MUCOPOLYSACCHARIDOSE TYPE I OR II
EP3826664A4 (en) 2019-02-06 2022-10-26 Sangamo Therapeutics, Inc. METHOD FOR THE TREATMENT OF TYPE I MUCOPOLYSACCHARIDOSES

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
AU2004210936C1 (en) 2003-02-11 2010-12-02 Takeda Pharmaceutical Company Limited Diagnosis and treatment of Multiple Sulfatase Deficiency and other using a Formylglycine Generating Enzyme (FGE)
WO2005113765A2 (en) * 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제

Also Published As

Publication number Publication date
EA026499B1 (ru) 2017-04-28
EA201490149A1 (ru) 2014-09-30
CY1117861T1 (el) 2017-05-17
JP2016056179A (ja) 2016-04-21
AU2016201487B2 (en) 2017-10-19
KR101158673B1 (ko) 2012-07-03
EP2723369A4 (en) 2014-12-24
SMT201600194B (it) 2016-08-31
EP2723369B2 (en) 2023-05-10
UA109949C2 (uk) 2015-10-26
MY166647A (en) 2018-07-18
CA2839674C (en) 2018-04-24
ES2575377T5 (es) 2023-10-26
US20150320843A1 (en) 2015-11-12
WO2012177020A2 (en) 2012-12-27
AU2016201487A1 (en) 2016-03-24
PL2723369T3 (pl) 2016-09-30
RS54822B2 (sr) 2023-09-29
PT2723369E (pt) 2016-06-03
CN103635203A (zh) 2014-03-12
RS54822B1 (sr) 2016-10-31
WO2012177020A3 (en) 2013-04-04
SI2723369T1 (sl) 2016-09-30
AU2012274215A1 (en) 2014-02-20
CN103635203B (zh) 2016-06-08
BR112013032193A2 (pt) 2017-11-21
EP2723369A2 (en) 2014-04-30
PE20140734A1 (es) 2014-07-04
JP6000432B2 (ja) 2016-09-28
KR20160030591A (ko) 2016-03-21
HUE027431T2 (en) 2016-09-28
US20140242059A1 (en) 2014-08-28
AU2012274215B2 (en) 2015-12-10
DK2723369T3 (en) 2016-06-13
US9206402B2 (en) 2015-12-08
US9249397B2 (en) 2016-02-02
MX2013015127A (es) 2014-06-11
HK1195731A1 (zh) 2014-11-21
CA2839674A1 (en) 2012-12-27
FI2723369T4 (fi) 2023-08-31
DK2723369T4 (da) 2023-07-24
KR101910124B1 (ko) 2018-10-19
HRP20160490T1 (hr) 2016-08-12
IL230120B (en) 2020-09-30
WO2012177020A9 (en) 2013-02-14
PL2723369T5 (pl) 2024-02-05
ES2575377T3 (es) 2016-06-28
NZ620284A (en) 2015-11-27
JP2014520143A (ja) 2014-08-21
HRP20160490T4 (hr) 2023-09-15
CO6862105A2 (es) 2014-02-10
EP2723369B1 (en) 2016-04-13
JP5844459B2 (ja) 2016-01-20
SI2723369T2 (sl) 2023-08-31

Similar Documents

Publication Publication Date Title
MX2013015127A (es) Composicion y formulacion que comprende iduronato - 2 - sulfatasa humana recombinante y metodo de preparacion de la misma.
MY179703A (en) Dry powder formulation comprising a phosphodiesterase inhibitor
MX2012012438A (es) Formulaciones farmaceuticas que comprenden pioglitazona y linagliptina.
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
ZA200810124B (en) Pharmaceutical combination comprising 3-(3-dimethyl-amino-1-ethyl-2-methyl-propyl)-phenol and Paracetamol
EP2818172A4 (en) TLR4 MEDIUM, TISSUE HOMEOSTAT, HEPATOCYTE GROWTH FACTOR INDUCTOR, TISSUE-DISAPPEARING AGENT, AND SIRTUINE INDUCTOR WITH HYALURONIC ACID FRAGMENTS AS ACTIVE AGENTS THEREOF
PH12014501545A1 (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
MD20140131A2 (ro) Doză şi formă preparativă nouă pentru inhalare care cuprinde aclidiniu
MX2015000485A (es) Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina.
WO2011093818A3 (en) Pharmaceutical compositions comprising salmeterol and fluticasone
WO2011076840A3 (en) Aerosol formulation for copd
IN2014MN02156A (es)
WO2012030308A3 (en) Formulation comprising cellobiose
GR1008228B (el) Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου
IN2014DN09240A (es)
EP2886112A4 (en) COMPOSITION CONTAINING AS ACTIVE INGREDIENT OF S-ALLYL-L-CYSTEINE FOR PREVENTING OR TREATING OCULAR DISEASES, AND PHARMACEUTICAL FORMULATION COMPRISING THE SAME
WO2013124832A3 (en) Stabilized controlled-release pharmaceutical composition comprising gliclazide
EP2431049A4 (en) Pharmaceutical preparation for administration to the respiratory system Prevention of inflammatory respiratory diseases and methods of treatment or PREVENTION OF SUCH DISEASES
HK1216253A1 (zh) 新型化合物、其藥學上可接受的鹽或光學異構體、用於製備它們的方法以及包含它們作為有效成分的用於預防或治療病毒性疾病的藥物組合物
EP3064201A4 (en) Pharmaceutical composition for preventing and treating central nervous system diseases containing fluoxetine and vitamin c as active ingredients
WO2014155268A3 (en) Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
UA97044C2 (ru) Средство противовирусной и иммуностимулирующей активности, способ получения средства противовирусной и иммуностимулирующей активности, способ профилактики и лечения инфекционных болезней
WO2011121475A3 (en) Modified release dosage form comprising desvenlafaxine or salts thereof

Legal Events

Date Code Title Description
FG Grant or registration